Cancer patients across Pittsburgh are getting a very different radiation experience these days. At UPMC Hillman Cancer Center, people who once had few options are now reporting shorter treatment courses, less collateral damage to healthy tissue, and real, measurable pain relief, as the network quietly rolls out a new generation of radiation tools.
From biology-guided systems that follow tumors as they move to camera-guided positioning and targeted radioactive drugs, Hillman is widening access to treatments that used to sound more like science fiction than standard care. The shift is the payoff from years of investment, clinical trials, and new equipment installations across UPMC’s Pittsburgh-area hospitals.
As highlighted in a recent report from CBS News Pittsburgh, clinicians and patients say the expanded radiation toolkit is already changing lives around the region. The segment featured patients whose mobility and pain improved after newer radiation approaches and described Hillman’s push as an effort to explore everything radiation treatment can treat.
Biology-guided radiotherapy follows tumors in real time
One of the headline technologies is biology-guided radiotherapy, the RefleXion X1 system, which integrates PET imaging with radiation to target moving tumors, according to Imaging Technology News. Hillman clinicians quoted in coverage note that PET has never before been used to guide radiation delivery in real time, a capability that can allow treatment of multiple tumors in a single session for some metastatic patients.
Precision positioning and shorter courses
UPMC has also deployed surface-guided radiation therapy, or SGRT, a camera-based system that maps a patient’s skin to improve setup and reduce movement during treatment, according to a UPMC news release. By minimizing motion and sharpening alignment, the technology helps clinicians deliver higher doses more safely and, for some patients, cut down the number of sessions needed.
Targeted radioactive drugs add another arrow
Beyond the big machines, Hillman teams are leaning into theranostics, targeted radioactive drugs that deliver radiation from inside the body, a strategy discussed by specialists on the Oncology Unscripted podcast. These radiopharmaceuticals can ease bone pain from metastases and offer systemic control for cancers such as prostate cancer and certain neuroendocrine tumors.
Hillman now offers radiopharmaceuticals such as Lutetium
UPMC Hillman’s patient education pages note that the center provides radiopharmaceuticals, including lutetium-177 agents used in prostate and neuroendocrine cancer care, according to UPMC Hillman. The site explains that these drugs travel through the bloodstream to target tumors and often bring measurable pain relief and tumor control without the recovery demands of surgery.
Clinicians stress that every case is highly individualized, and not everyone is a candidate for these newer options. Still, they say the combination of upgraded machines, drug therapies, and clinical trials is already expanding who can safely receive radiation. Local providers describe the trend as a move toward more precise, less invasive cancer care in the Pittsburgh region. As the CBS coverage and Hillman clinicians have made clear, this is not a cure-all, but it has quickly become a crucial new set of tools in the oncology toolbox.
